{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Kidney&page=59",
    "query": {
      "condition": "Kidney",
      "page": 59
    },
    "page_size": 10
  },
  "pagination": {
    "page": 59,
    "page_size": 10,
    "total_count": 6448,
    "total_pages": 645,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Kidney&page=60&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Kidney&page=58&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-05T09:57:05.801Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00543075",
      "title": "Pharmacokinetic Study of Genasense in Subjects With Normal Renal Function, Mildly Impaired Renal Function, and Moderately Impaired Renal Function",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Normal Renal Function",
        "Mildly Impaired Renal Function",
        "Moderately Impaired Renal Function"
      ],
      "interventions": [
        {
          "name": "Genasense (oblimersen, G3139)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genta Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Weeks",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Weeks and older"
      },
      "enrollment_count": 23,
      "start_date": "2006-05",
      "completion_date": "2009-09",
      "has_results": false,
      "last_update_posted_date": "2012-03-13",
      "last_synced_at": "2026-11-05T09:57:05.801Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00543075"
    },
    {
      "nct_id": "NCT02438267",
      "title": "Preterm Infants and Nephrocalcinosis",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Prematurity",
        "Nephrocalcinosis",
        "Hypercalciuria"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University of Utah",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "2 Weeks",
        "sex": "ALL",
        "summary": "Up to 2 Weeks"
      },
      "enrollment_count": 56,
      "start_date": "2015-04",
      "completion_date": "2017-01",
      "has_results": false,
      "last_update_posted_date": "2017-03-13",
      "last_synced_at": "2026-11-05T09:57:05.801Z",
      "location_count": 1,
      "location_summary": "Murray, Utah",
      "locations": [
        {
          "city": "Murray",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02438267"
    },
    {
      "nct_id": "NCT03150667",
      "title": "Study Comparing Treatment Effectiveness of Guideline Indicated APT for ACS in Patients With CKD",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Chronic Kidney Diseases",
        "Acute Coronary Syndrome"
      ],
      "interventions": [
        {
          "name": "Ticagrelor",
          "type": "DRUG"
        },
        {
          "name": "Clopidogrel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "North Texas Veterans Healthcare System",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 220,
      "start_date": "2017-04-10",
      "completion_date": "2020-04-30",
      "has_results": false,
      "last_update_posted_date": "2018-05-25",
      "last_synced_at": "2026-11-05T09:57:05.801Z",
      "location_count": 2,
      "location_summary": "Durham, North Carolina • Dallas, Texas",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03150667"
    },
    {
      "nct_id": "NCT05001009",
      "title": "Goals of Care Conversations Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Seriously Ill Patients",
        "Cancer",
        "Heart Failure",
        "Interstitial Lung Disease",
        "Chronic Obstructive Pulmonary Disease",
        "End-stage Renal Disease",
        "End-stage Liver Disease",
        "Dementia"
      ],
      "interventions": [
        {
          "name": "Clinician Implementation Strategy Stage 1: low intensity clinician training",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Clinician Implementation Strategy Stage 2: high intensity clinician training",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Low patient engagement",
          "type": "BEHAVIORAL"
        },
        {
          "name": "High patient engagement",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "VA Office of Research and Development",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2859,
      "start_date": "2022-09-13",
      "completion_date": "2025-09-30",
      "has_results": true,
      "last_update_posted_date": "2026-09-16",
      "last_synced_at": "2026-11-05T09:57:05.801Z",
      "location_count": 3,
      "location_summary": "Palo Alto, California • West Los Angeles, California • Aurora, Colorado",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "West Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05001009"
    },
    {
      "nct_id": "NCT04228042",
      "title": "Infigratinib Before Surgery for the Treatment of Upper Tract Urothelial Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Renal Pelvis and Ureter Urothelial Carcinoma"
      ],
      "interventions": [
        {
          "name": "Infigratinib",
          "type": "DRUG"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Surgical Procedure",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2020-07-28",
      "completion_date": "2024-04-17",
      "has_results": true,
      "last_update_posted_date": "2025-01-01",
      "last_synced_at": "2026-11-05T09:57:05.801Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04228042"
    },
    {
      "nct_id": "NCT01984242",
      "title": "A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) as Monotherapy or in Combination With Bevacizumab (Avastin®) Compared to Sunitinib (Sutent®) in Participants With Untreated Advanced Renal Cell Carcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Renal Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "Sunitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 305,
      "start_date": "2014-01-08",
      "completion_date": "2019-01-08",
      "has_results": true,
      "last_update_posted_date": "2019-12-23",
      "last_synced_at": "2026-11-05T09:57:05.801Z",
      "location_count": 25,
      "location_summary": "Scottsdale, Arizona • Duarte, California • Los Angeles, California + 19 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01984242"
    },
    {
      "nct_id": "NCT02417870",
      "title": "Ultra-low Dose Subcutaneous IL-2 in Renal Transplantation",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Kidney Transplantation"
      ],
      "interventions": [
        {
          "name": "aldesleukin",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Anil K. Chandraker, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 2,
      "start_date": "2015-09",
      "completion_date": "2018-04",
      "has_results": true,
      "last_update_posted_date": "2021-06-24",
      "last_synced_at": "2026-11-05T09:57:05.801Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02417870"
    },
    {
      "nct_id": "NCT00816686",
      "title": "A Phase 1 Study of the Safety and Pharmacokinetics of AGS-16M18 in Subjects With Advanced Renal Cell Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Carcinoma, Renal Cell",
        "Kidney Neoplasms",
        "Kidney Diseases"
      ],
      "interventions": [
        {
          "name": "AGS-16M18",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Astellas Pharma Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 7,
      "start_date": "2008-10",
      "completion_date": "2010-04",
      "has_results": false,
      "last_update_posted_date": "2013-02-27",
      "last_synced_at": "2026-11-05T09:57:05.801Z",
      "location_count": 2,
      "location_summary": "Baltimore, Maryland • New York, New York",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00816686"
    },
    {
      "nct_id": "NCT00045370",
      "title": "Chemotherapy and Biological Therapy in Treating Patients With Locally Advanced or Metastatic Kidney Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Kidney Cancer"
      ],
      "interventions": [
        {
          "name": "recombinant interferon alfa",
          "type": "BIOLOGICAL"
        },
        {
          "name": "temsirolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "2002-04",
      "completion_date": "2003-11",
      "has_results": false,
      "last_update_posted_date": "2013-06-05",
      "last_synced_at": "2026-11-05T09:57:05.801Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00045370"
    },
    {
      "nct_id": "NCT04745169",
      "title": "Home-Based Exercise to Treat Decreased Physical Function in Patients With Varying Levels of Kidney Function",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Chronic Kidney Disease"
      ],
      "interventions": [
        {
          "name": "8 week home-based exercise program",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Baylor College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2020-12-21",
      "completion_date": "2023-11-16",
      "has_results": true,
      "last_update_posted_date": "2025-08-17",
      "last_synced_at": "2026-11-05T09:57:05.801Z",
      "location_count": 2,
      "location_summary": "Rochester, Minnesota • Houston, Texas",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04745169"
    }
  ]
}